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CORRESPONDENCE
Re: Stem Cell Transplant
Numbers Decline;
Research Continues
A recent news item (1) in the Journal
presents data generated from the Au-
tologous Bone Marrow Transplant Reg-
istry in North America and reports a
marked decline in autologous hemato-
poietic stem cell transplants (HSCT) in
North America from 1998 through 1999.
A similar trend is predicted for alloge-
neic HSCT, and some of the reasons are
discussed. We would like to extend
these observations with data from the
European Group for Blood and Marrow
Transplantation (EBMT), point to simi-
larities and differences, and add other
potential reasons for the reported declines.
Since 1990, EBMT has been collect-
ing and reporting annually the numbers
of HSCT in Europe according to disease
indication, donor type, and stem cell
source (2). These reports cover virtually
all major transplant teams and more than
90% of all HSCT performed in Europe.
For 1999, a total of 21 430 HSCT were
performed by 580 teams in 35 European
countries. Of these HSCT, 18 720 were
first transplants, with 5879 (31%) of
them being allogeneic and 12 841 (69%)
of them being autologous (3).
Fig. 1 shows the development since
1990 for allogeneic (top panel) and au-
tologous (bottom panel) HSCT. Alloge-
neic HSCT have continued to increase
as in previous years, with 571 more
transplants in 1999 (5879) than in 1998
(5308). In contrast, there has been an ab-
solute decrease of 252 autologous HSCT
from 13 092 in 1998 to 12 841 in 1999.
There are differences between the
disease indications. Allogeneic HSCT
have increased for all disease categories,
with the exception of severe aplastic
anemia, thalassemia, where numbers
have remained stable. An increase in au-
tologous HSCT was observed for acute
myeloid leukemia, myelodysplastic syn-
dromes, chronic lymphocytic leukemia,
multiple myeloma, Hodgkin’s disease,
neuroblastoma, germ cell cancer, and
Ewing’s sarcoma. A decrease in autolo-
gous HSCT was observed for acute lym-
phocytic leukemia, chronic myeloid
leukemia, non-Hodgkin’s lymphoma,
soft-tissue sarcomas, ovarian cancer,
and most markedly for breast cancer,
with 692 HSCT fewer in 1999 than in
1998 (1682 versus 2374). This decrease
in autologous HSCT for breast cancer
already began in 1998 and peaked in
1997 (4).
The activity surveys do not reveal
reasons for the increase or the decrease
in rates of HSCT for given disease indi-
cations. They only present the data.
Medical reasons were discussed previ-
ously by Twombly (1). The EBMT ac-
tivity survey, based on more than 600
teams (the teams were contacted, and
580 replied in 1999—an approximately
95% return), points to an additional
problem. Several teams, especially the
smaller ones, personally communicated
their reluctance to present their numbers
for publications. Ongoing discussions
on constraints and health-care regula-
tions in transplantation medicine might
influence such decisions. Hence, under-
reporting might, in part, explain some of
the differences between Europe and the
United States.
In summary, comprehensive Euro-
pean data show a continuing increase in
HSCT for most indications and a dis-
tinct reduction in activity for autologous
HSCT in breast cancer. Generalizations
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Fig. 1. Top panel: numbers of
allogeneic hematopoietic stem
cell transplants (HSCT) in Eu-
rope (first transplants only)
from 1990 through 1999. Bot-
tom panel: numbers of autolo-
gous HSCT in Europe (first
transplants only) from 1990
through 1999. EBMT Euro-
pean Group for Blood and
Marrow Transplantation.
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